<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dugger SA</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>Robins Family Foundation</funding><funding>NCATS NIH HHS</funding><funding>T32 National Research Service Award</funding><funding>NINDS NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>e1010952</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10569524</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(10)</volume><pubmed_abstract>Heterozygous de novo loss-of-function mutations in the gene expression regulator HNRNPU cause an early-onset developmental and epileptic encephalopathy. To gain insight into pathological mechanisms and lay the potential groundwork for developing targeted therapies, we characterized the neurophysiologic and cell-type-specific transcriptomic consequences of a mouse model of HNRNPU haploinsufficiency. Heterozygous mutants demonstrated global developmental delay, impaired ultrasonic vocalizations, cognitive dysfunction and increased seizure susceptibility, thus modeling aspects of the human disease. Single-cell RNA-sequencing of hippocampal and neocortical cells revealed widespread, yet modest, dysregulation of gene expression across mutant neuronal subtypes. We observed an increased burden of</pubmed_abstract><journal>PLoS genetics</journal><pubmed_title>Neurodevelopmental deficits and cell-type-specific transcriptomic perturbations in a mouse model of HNRNPU haploinsufficiency.</pubmed_title><pmcid>PMC10569524</pmcid><funding_grant_id>R37 NS031348</funding_grant_id><funding_grant_id>T32 GM007367</funding_grant_id><funding_grant_id>GM007367</funding_grant_id><funding_grant_id>Private family foundation</funding_grant_id><funding_grant_id>TL1 TR001875</funding_grant_id><funding_grant_id>TL1TR001875</funding_grant_id><pubmed_authors>Peng Y</pubmed_authors><pubmed_authors>Dhindsa RS</pubmed_authors><pubmed_authors>Rafikian EE</pubmed_authors><pubmed_authors>Goldstein DB</pubmed_authors><pubmed_authors>Yang M</pubmed_authors><pubmed_authors>Letts VA</pubmed_authors><pubmed_authors>Ressler AK</pubmed_authors><pubmed_authors>Petri S</pubmed_authors><pubmed_authors>Teoh J</pubmed_authors><pubmed_authors>Dugger SA</pubmed_authors><pubmed_authors>Boland MJ</pubmed_authors><pubmed_authors>Colombo S</pubmed_authors><pubmed_authors>Frankel WN</pubmed_authors><pubmed_authors>Sampaio GA</pubmed_authors><pubmed_authors>Ye J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Neurodevelopmental deficits and cell-type-specific transcriptomic perturbations in a mouse model of HNRNPU haploinsufficiency.</name><description>Heterozygous de novo loss-of-function mutations in the gene expression regulator HNRNPU cause an early-onset developmental and epileptic encephalopathy. To gain insight into pathological mechanisms and lay the potential groundwork for developing targeted therapies, we characterized the neurophysiologic and cell-type-specific transcriptomic consequences of a mouse model of HNRNPU haploinsufficiency. Heterozygous mutants demonstrated global developmental delay, impaired ultrasonic vocalizations, cognitive dysfunction and increased seizure susceptibility, thus modeling aspects of the human disease. Single-cell RNA-sequencing of hippocampal and neocortical cells revealed widespread, yet modest, dysregulation of gene expression across mutant neuronal subtypes. We observed an increased burden of</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-07-14T22:03:18.413Z</modification><creation>2025-04-05T12:06:03.212Z</creation></dates><accession>S-EPMC10569524</accession><cross_references><pubmed>37782669</pubmed><doi>10.1371/journal.pgen.1010952</doi></cross_references></HashMap>